Updated: 8/10/11 9:30 a.m.
Abbott Laboratories (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) came out as the big players in the U.S. drug-eluting stent market, together staking claim to more than half of all DES revenues.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
More news from the Emerald Isle as the Boston Scientific Corp. (NYSE:BSX) plans to spend $37 million on overseas research and development, this time at its R&D facility in Clonmel, Ireland.
The Natick, Mass.-based company hopes to jump-start development of a next generation cardiac rhythm management system.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
A federal appeals court disappointed a group of Boston Scientific Corp. (NYSE:BSX) shareholders hoping to recoup losses stemming from a recall of the Taxus Express drug-eluting stent, upholding a lower court decision to dismiss a securities fraud lawsuit.
Medtronic Inc. (NYSE:MDT) has big plans for China, eyeing mergers and acquisitions and predicting twice as many China employees in the next four years.
The Minneapolis, Minn.-based med-tech giant’s Chinese workforce should hit 2,000 by 2016, spanning positions from engineering to sales.
The FDA granted Medtronic Inc. (NYSE:MDT) the go-ahead on a clinical trial to test its next generation of MRI pacemaker technology, the company announced today.
The Minneapolis, Minn.-based med-tech giant can enroll up to 250 patients in 50 medical centers across Europe, Central Asia, the U.S., Canada and Australia to test its new Advisa SureScan pacing system, Medtronic spokeswoman Wendy Dougherty said.
The shakeup at Boston Scientific (NYSE:BSX) last week proved that while the sheriff may be headed for the sunset, he’s not ready to hang up his spurs just yet.
With little more than a month past his two year anniversary of taking the helm at BSX, J. Raymond Elliott continues to re-shape the Natick, Mass.-based medical device colossus, despite the fact that he is essentially a lame duck with just a few months left in his current position as CEO until his scheduled retirement at the end of December.
Hospital purchasing organization Premier Inc. announced a fifth contract this week with news that the Charlotte, N.C.-based GPO would begin providing creatinine hand-held analyzers to certain levels of its membership.
The devices, which are used to assess renal function at bedside, are developed by Nova Biomedical Corp. of Waltham, Mass.
A rebounding Boston Scientific Corp. (NYSE:BSX) said it plans to eliminate up to 1,400 jobs as part of a restructuring program aimed at saving between $225 million to $275 million annually by 2013.
Stryker Corp.’s (NYSE:SYK) coffers look significantly thinner these days, after the company blew through about 71 percent of its cash and cash equivalents during the first half of 2011 on acquisitions.
A rebounding Boston Scientific Corp. (NYSE:BSX) said it plans to eliminate up to 1,400 jobs as part of a restructuring program aimed at saving between $225 million to $275 million annually by 2013.